Hildebrandt P
Hvidøre Hospital, Gentofte.
Dan Med Bull. 1991 Aug;38(4):337-46.
One major problem encountered when treating diabetic patients with insulin is the very large inter- and intra-individual variability in subcutaneous insulin absorption, a major contributory factor in the variability of the blood glucose level. Thus, to optimize insulin treatment the factors influencing the absorption have to be known and possibly utilized. The different types of insulin ("short-acting", "intermediate-acting" and "long-acting") have different times of action. "Short-acting" and "intermediate-acting" human insulin are probably absorbed slightly faster than porcine (and bovine) insulin. "Long-acting" human insulin is absorbed significantly faster than bovine insulin. More concentrated "short-acting" insulin (100 IU/ml) is absorbed slightly slower than less concentrated insulins (40 IU/ml). The absorption of "intermediate-acting" and "long-acting" insulin is dose-dependent, with a decreasing absorption rate with increasing dose of insulin. Insulin is administered subcutaneously either by injection or by using an infusion pump. The injection technique influences the absorption rate. Giving a continuous subcutaneous insulin infusion as a basal rate infusion, a depot is built-up. The building-up and the size of the depot, as well as the blood glucose and plasma insulin levels during steady-state conditions, are independent of the pulse-rate interval of the pump used (5 min vs 1 h). The size of the steady-state depot is constant during constant conditions but inversely correlated to the local subcutaneous blood flow and directly correlated to the infusion rate. An increase or decrease in the infusion rate during a basal rate infusion will after a delay of 2-3 h induce corresponding changes in the insulin absorption rate from the depot. After termination of the infusion, the insulin depot will still provide some insulin supply for 2-3 h. During the continuous infusion, the pharmacokinetics of the superimposed preprandial boluses will resemble injections of soluble insulin. The inter- and intra-individual variability in the insulin absorption, even when giving the same type, species, concentration and dose of insulin, is presumably primarily due to different and changing diffusion conditions in the subcutaneous tissue. Some factors which influence the diffusion conditions include exercise, local massage and, especially, local subcutaneous blood flow. Alterations in the blood flow induce, with a hyperbolic relationship, changes in the same direction in the absorption rate of injected and infused "short-acting" insulin and of injected "intermediate-acting" insulin. Several factors have been shown to influence both subcutaneous blood flow and insulin absorption, e.g. injection site, skinfold thickness, smoking, orthostatic changes, ketosis and ambient temperature.(ABSTRACT TRUNCATED AT 400 WORDS)
用胰岛素治疗糖尿病患者时遇到的一个主要问题是皮下胰岛素吸收存在非常大的个体间和个体内差异,这是血糖水平波动的一个主要促成因素。因此,为了优化胰岛素治疗,必须了解并可能利用影响吸收的因素。不同类型的胰岛素(“短效”、“中效”和“长效”)作用时间不同。“短效”和“中效”人胰岛素的吸收可能比猪(和牛)胰岛素稍快。“长效”人胰岛素的吸收明显快于牛胰岛素。更浓缩的“短效”胰岛素(100 IU/ml)的吸收比浓度较低的胰岛素(40 IU/ml)稍慢。“中效”和“长效”胰岛素的吸收呈剂量依赖性,胰岛素剂量增加时吸收速率降低。胰岛素通过注射或使用输液泵皮下给药。注射技术会影响吸收速率。以基础速率输注进行持续皮下胰岛素输注时,会形成一个储存库。储存库的形成和大小,以及稳态条件下的血糖和血浆胰岛素水平,与所用泵的脉冲速率间隔(5分钟对1小时)无关。在恒定条件下,稳态储存库的大小是恒定的,但与局部皮下血流呈负相关,与输注速率呈正相关。基础速率输注期间输注速率的增加或减少将在延迟2 - 3小时后引起储存库胰岛素吸收速率的相应变化。输注终止后,胰岛素储存库仍将提供2 - 3小时的胰岛素供应。在持续输注期间,叠加的餐前大剂量胰岛素的药代动力学将类似于可溶性胰岛素注射。即使给予相同类型、种类、浓度和剂量的胰岛素,胰岛素吸收的个体间和个体内差异可能主要是由于皮下组织中不同且不断变化的扩散条件。一些影响扩散条件的因素包括运动、局部按摩,尤其是局部皮下血流。血流变化以双曲线关系引起注射和输注的“短效”胰岛素以及注射的“中效”胰岛素吸收速率的同向变化。已显示有几个因素会影响皮下血流和胰岛素吸收,例如注射部位、皮褶厚度、吸烟、体位变化、酮症和环境温度。(摘要截取自400字)